Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma

Annals of Surgical Oncology

Volumn 4, Issue 4, 1997, Pages 334-341

  Lipshy, Kenneth A ^a   Kostuchenko, Paul J ^a   Hamad, Giselle G ^a   Bland, Christin E ^a   Barrett, Sandra K ^a   Bear, Harry D ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bryostatin; Immunotherapy; Ionomycin; Melanoma; T lymphocytes; Vaccine

Indexed keywords

BRYOSTATIN 1; CANCER VACCINE; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; LACTONE; MACROLIDE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; ARTICLE; C57BL MOUSE; CELL CULTURE; EXPERIMENTAL MELANOMA; FEMALE; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; LUNG TUMOR; METASTASIS; METHODOLOGY; MOUSE; SECRETION; T LYMPHOCYTE; TUMOR REGRESSION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CYTOKINES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOTHERAPY, ADOPTIVE; LACTONES; LUNG NEOPLASMS; MACROLIDES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM REGRESSION, SPONTANEOUS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0031154377     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02303584     Document Type: Article

References (24)

1. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993;90:3539-43.
2. Colombo MP, Ferrari G, Stoppacciaro A, et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991;173:889-97.
3. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-24.
4. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin 4. Science 1991;254:713-6.
5. Krauss JC, Storme SE, Chang AE, Shu S. Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4. J Immunother 1994;16:77-84.
6. Tuttle TM, Inge TH, Bethke KP, McCrady CW, Pettit GR, Bear HD. Activation and growth of murine tumor-specific T cells which have in vivo activity with bryostatin 1. Cancer Res 1992;52:548-53.
7. Pettit GR, Day JF, Harwell JL, Wood HB. Antineoplastic components of marine animals. Nature 1970;227:962-3.
8. Tuttle TM, Inge TH, Lind DS, Bear HD. Adoptive transfer of bryostatin 1-activated T cells provides long-term protection from tumour metastases. Surg Oncol 1992;1:299-307.
9. Herlyn M, Kaprowski H. Melanoma antigens. Immunological and biological characterization and clinical significance. Ann Rev Immunol 1988;6:283-308.
10. Fidler IJ. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 1975;35:218-24.
11. Hart IR. The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol 1979;97:587-600.
12. Maslow DE. Tabulation of results on the heterogeneity of cellular characteristics among cells from B16 mouse melanoma cell lines with different colonization potentials: a summary of sixty reports. Invasion Metastasis 1989;9:182-91.
13. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957;18:769-78.
14. Geiger JD, Wagner PD, Cameron MJ, Shu S, Chang AE. Generation of T cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. J Immunother 1993;13:153-65.
15. Keller R, Keist R, Leist TP, Van Der Meide PH. Resistance to a non-immunogenic tumor, induced by Corynebacterium parvum or Listeria monocytogenes, is abrogated by anti-interferon gamma. Int J Cancer 1990;46:687-90.
16. Hock H, Dorsch M, Kunzendorf U, et al. Vaccinations with tumor cells genetically engineered to produce different cytokines: effectively not superior to a classical adjuvant. Cancer Res 1993;53:714-6.
17. Dye ES, North RJ, Mills CD. Mechanisms of antitumor action of Corynebacterium parvum. I. Potentiated anti-tumor-specific immunity and its therapeutic limitations. J Exp Med 1981;154:609-20.
18. Hock H, Dorsch M, Kunzendorf U, et al. Vaccination with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res 1993;53:714-6.
19. Mitchison NA, Phil D. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med 1955;102:157-77.
20. Shu S, Chou T, Sakai K. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J Immunol 1989;143:740-8.
21. Schmidt W, Schweighoffer T, Herbst E, et al. Cancer vaccines: the interleukin 2 dosage effect. Proc Natl Acad Sci U S A 1995;92:4711-4.
22. Zoller M, Strubel A, Hammerling G, Andrighetto G, Raz A, Ben Ze'ev A. Interferon-gamma treatment of B16 melanoma cells: opposing effects for non-adaptive and adaptive immune defense and its reflection by metastatic spread. Int J Cancer 1988;41:256-66.
23. Hara I, Nguyen H, Takechi Y, Gansbacher B, Chapman PB, Houghton AN. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophage without T cells or natural killer cells in tumor rejection. Int J Cancer 1995;61:253-60.
24. Maas G, Schmidt W, Berger M, et al. Priming of tumor-specific T cells in the draining lymph nodes after immunization with Interleukin-2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci U S A 1995;92:5540-4.